| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Heron Therapeutics, Inc. /de/ (HRTX) has 11 insiders with recent SEC Form 4 filings, including 5 buys and 5 sells. HRTX is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| 10% | 30.05M | $27.86M | - | |
| CEO | 662.1K | $613.8K | - | |
| CFO | 215.9K | $200.1K | - | |
| COO | 188.3K | $174.6K | - | |
| Dir | 123.7K | $114.7K | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| May 1, 2020 | Manhard Kimberly80 | Executive VP, Drug Development | Sell | 1,158 | $13.97 | $16,175.75 | -100% | |
| Nov 29, 2019 | Manhard Kimberly80 | Executive VP, Drug Development | Sale+OE | 24,000 | $26.00 | $624,000.00 | -100% | |
| Oct 4, 2019 | Tang Kevin C86 | Director | Buy | 285,714 | $17.50 | $4,999,995.00 | +5.2% | |
| Oct 3, 2019 | Quart Barry D61 | Chief Executive Officer | Buy | 4,571 | $17.50 | $79,992.50 | +5.1% | |
| Oct 3, 2019 | Poyhonen John | EVP, Chief Commercial Officer | Buy | 5,143 | $17.50 | $90,002.50 | +39.6% | |
| May 22, 2019 | Poyhonen John | Director | Buy | 3,000 | $17.55 | $52,650.00 | +30.0% | |
| May 15, 2019 | Christian Waage75 | Director | Buy | 1,400 | $18.04 | $25,261.74 | New | |
| May 1, 2019 | Manhard Kimberly80 | Executive VP, Drug Development | Sell | 1,109 | $18.86 | $20,918.07 | -100% | |
| Nov 2, 2018 | Manhard Kimberly80 | Executive VP, Drug Development | Sell | 494 | $30.62 | $15,124.95 | -100% | |
| Oct 1, 2018 | Manhard Kimberly80 | Executive VP, Drug Development | Sale+OE | 6,000 | $32.07 | $192,433.20 | -100% |